Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Asia: A Non-interventional Study
Phase of Trial: Phase IV
Latest Information Update: 27 Sep 2017
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism; Stroke; Thromboembolism
- Focus Adverse reactions
- Acronyms XANAP
- Sponsors Bayer
- 30 Aug 2017 Results of pooled analysis of three observational studies (XANTUS, XANAP and XANTUS-EL) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 20 May 2016 Status changed from recruiting to completed.
- 18 Jul 2014 Planned primary completion date changed from 1 Jul 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.